+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuroblastoma - Pipeline Review, H2 2019

  • ID: 4901269
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 895 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Biotec Pharmacon ASA
  • Epigene Therapeutics Inc
  • Juno Therapeutics Inc
  • OncoTherapy Science Inc
  • Rophibio Inc
  • MORE
Neuroblastoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2019, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 42, 20, 2, 46, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 6, 1, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Biotec Pharmacon ASA
  • Epigene Therapeutics Inc
  • Juno Therapeutics Inc
  • OncoTherapy Science Inc
  • Rophibio Inc
  • MORE
Introduction
Neuroblastoma - Overview
Neuroblastoma - Therapeutics Development
Neuroblastoma - Therapeutics Assessment
Neuroblastoma - Companies Involved in Therapeutics Development
Neuroblastoma - Drug Profiles
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Neuroblastoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuroblastoma - Pipeline by 4D Pharma Plc, H2 2019
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2019
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H2 2019
Neuroblastoma - Pipeline by ADC Therapeutics SA, H2 2019
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2019
Neuroblastoma - Pipeline by Alissa Pharma, H2 2019
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2019
Neuroblastoma - Pipeline by Aptorum Group Ltd, H2 2019
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2019
Neuroblastoma - Pipeline by AUM Biosciences Pte Ltd, H2 2019
Neuroblastoma - Pipeline by Autolus Therapeutics Plc, H2 2019
Neuroblastoma - Pipeline by Bayer AG, H2 2019
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019

List of Figures
Number of Products under Development for Neuroblastoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Pharma Plc
  • Ability Pharmaceuticals SL
  • Actuate Therapeutics Inc
  • ADC Therapeutics SA
  • Advanced Accelerator Applications SA
  • Alissa Pharma
  • APEIRON Biologics AG
  • Aptorum Group Ltd
  • AstraZeneca Plc
  • AUM Biosciences Pte Ltd
  • Autolus Therapeutics Plc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • Bio-Cancer Treatment International Ltd
  • Biogenera SpA
  • BioLineRx Ltd
  • Biotec Pharmacon ASA
  • BioVec Pharma Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cancer Prevention Pharmaceuticals Inc
  • Cebiotex SL
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Chiome Bioscience Inc
  • Clarity Pharmaceuticals Pty Ltd
  • Cleveland BioLabs Inc
  • CorMedix Inc
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • DEKK-TEC Inc
  • Eli Lilly and Co
  • Epigene Therapeutics Inc
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GC Pharma
  • Gibson Oncology LLC
  • GlaxoSmithKline Plc
  • Healx Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • Helixmith Co Ltd
  • HRAIN Biotechnology Co Ltd
  • ID Pharma Co Ltd
  • Invenra Inc
  • Ipsen SA
  • Jubilant DraxImage Inc
  • Juno Therapeutics Inc
  • KC Pharma LLC
  • Lead Discovery Center GmbH
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Morphogenesis Inc
  • Nanogenics Ltd
  • NanoPharmaceuticals LLC
  • Novartis AG
  • OGD2 Pharma SAS
  • Ohara Pharmaceutical Co Ltd
  • Oncology Venture U.S. Inc
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Open Therapeutics LLC
  • Orphelia Pharma SAS
  • Oxurion NV
  • Panorama Research Inc
  • Pfizer Inc
  • Phylogica Ltd
  • Progenics Pharmaceuticals Inc
  • Provectus Biopharmaceuticals Inc
  • Recombio SL
  • RedHill Biopharma Ltd
  • resTORbio Inc
  • Ribomic Inc
  • Rophibio Inc
  • Sapience Therapeutics Inc
  • SciTech Development LLC
  • Seneca Therapeutics Inc
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • SignalRx Pharmaceuticals Inc
  • Sinobioway Cell Therapy Co Ltd
  • SMTPH Ltd
  • Sorrento Therapeutics Inc
  • Tactiva Therapeutics LLC
  • TheraBiologics Inc
  • Tmunity Therapeutics Inc
  • Toko Pharmaceutical Industries Co Ltd
  • Transtarget Inc
  • Trellis Bioscience Inc
  • TroBio Therapeutics Pty Ltd
  • Xcovery Holding Company LLC
  • Y-Biologics
  • Y-mAbs Therapeutics Inc
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
Adroll
adroll